
超声弹性成像技术联合血清甲胎蛋白、γ-谷氨酰转肽酶检验诊断肝脏良恶性肿瘤的价值
The value of ultrasound elastography combined with serum alpha fetoprotein and γ-glutamyl transpeptidase assay in the diagnosis of benign and malignant tumors of the liver
目的:分析超声弹性成像技术联合血清甲胎蛋白(AFP)、γ-谷氨酰转肽酶(GGT)检验诊断肝脏良恶性肿瘤的应用价值。方法:选取肝脏恶性病变(恶心组)及良性病变(良性组)患者各40例,均进行超声弹性成像检查,测定血清AFP、GGT水平,分析其对肝脏良恶性诊断的价值。结果:恶性组弹性硬度评分及血清AFP、GGT水平均高于良性组(P<0.05)。超声弹性成像弹性硬度评分、S1S2指数联合血清AFP和GGT检验诊断肝脏良恶性肿瘤的敏感度为100.00%,特异度为97.50%,均高于单一指标(P<0.05)。结论:超声弹性成像联合血清AFP、GGT检验诊断肝脏良恶性肿瘤的临床价值高。
Objective: To analyze the application value of the combination of ultrasound elastography with serum alpha fetoprotein (AFP) and γ-glutamyl transpeptidase (GGT) assay in the diagnosis of benign and malignant tumors of the liver. Methods: Forty patients with malignant liver lesions (malignant group) and 40 patients with benign liver lesions (benign group) were selected for ultrasound elastography examination, and their serum AFP and GGT levels were determined to analyze their diagnostic value for benign and malignant liver lesions. Results: The elastic hardness scores and the serum AFP and GGT levels were higher in the malignant group than the benign group (P<0.05). The sensitivity and specificity of ultrasound elastography elastic hardness scores, S1S2 index combined with serum AFP and GGT levels for the diagnosis of benign and malignant tumors of the liver were 100.00% and 97.50%, which were all higher than the single index (P<0.05). Conclusion: Ultrasound elastography combined with serum AFP and GGT levels has high clinical value in the diagnosis of benign and malignant tumors of the liver.
超声弹性成像 / 甲胎蛋白 / γ-谷氨酰转肽酶 / 肝脏良恶性肿瘤 {{custom_keyword}} /
ultrasound elastography / alpha fetoprotein / γ-glutamyl transpeptidase / benign and malignant tumors of the liver {{custom_keyword}} /
表1 患者基线资料比较 |
组别 | 男/女 | 年龄/岁 | 肿瘤最大 径/cm | 体质量指数/(kg·m−2) |
---|---|---|---|---|
恶性组(n=40) | 21/19 | 53.30±2.07 | 7.48±1.06 | 21.92±1.82 |
良性组(n=40) | 23/17 | 52.81±2.10 | 7.51±1.08 | 22.01±1.85 |
χ2/t值 | 0.202 | 1.051 | 0.125 | 0.219 |
P值 | 0.653 | 0.297 | 0.901 | 0.827 |
表2 患者超声弹性参数比较 ( |
组别 | 弹性硬度评分 | S1/kPa | S2/kPa | S1S2指数 |
---|---|---|---|---|
恶性组(n=40) | 4.05±1.04 | 11.83±4.86 | 9.10±3.09 | 13.10±4.01 |
良性组(n=40) | 1.98±0.43 | 6.89±1.08 | 5.78±1.15 | 6.82±1.37 |
t值 | 11.633 | 6.276 | 6.369 | 9.373 |
P值 | <0.001 | <0.001 | <0.001 | <0.001 |
表3 血清AFP、GGT水平比较 ( |
组别 | AFP/(ng·mL−1) | GGT/(U·L−1) |
---|---|---|
恶性组(n=40) | 138.52±48.91 | 118.84±31.74 |
良性组(n=40) | 25.18±6.39 | 65.48±19.51 |
t值 | 14.533 | 9.058 |
P值 | <0.001 | <0.001 |
表4 比较超声弹性成像联合血清AFP、GGT检验诊断肝脏良恶性肿瘤的价值 |
指标 | 截断值 | AUC | P值 | 95%CI | 约登指数 | 敏感度/% | 特异度/% |
---|---|---|---|---|---|---|---|
弹性硬度评分 | >1.835 | 0.917 | <0.001 | 0.852~0.981 | 0.650 | 60.00 | 75.00 |
S1S2指数 | >6.890 | 0.914 | <0.001 | 0.849~0.980 | 0.650 | 57.50 | 75.00 |
AFP | >118.00 ng/mL | 0.846 | <0.001 | 0.759~0.933 | 0.800 | 87.50 | 32.50 |
GGT | >84.69 U/L | 0.901 | <0.001 | 0.831~0.971 | 0.450 | 75.00 | 75.00 |
联合指标 | 0.989 | <0.001 | 0.966~1.000 | 0.975 | 100.00a) | 97.50a) |
注:a) 与其他指标比较,P<0.05。 |
[1] |
The natural history and incidence of hepatocellular carcinoma (HCC) arising from indeterminate liver lesions are not well described. We aimed to define the incidence of HCC in a cohort of patients undergoing surveillance by magnetic resonance imaging (MRI) and estimate any associations with incident HCC.We performed a retrospective follow-up study, identifying MRI scans in which indeterminate lesions had been reported between January 2006 and January 2017. Subsequent MRI scan reports were reviewed for incident HCC arising from indeterminate lesions, data were extracted from electronic patient records and survival analysis performed to estimate associations with baseline factors.One hundred and nine patients with indeterminate lesions on MRI were identified. HCC developed in 19 (17%) patients over mean follow up of 4.6 years. Univariate Cox proportional hazards analysis found incident HCC to be significantly associated with baseline low platelet count (hazard ratio (HR) = 7.3 (95% confidence intervals (CI) 2.1-24.9), high serum alpha-fetoprotein level (HR = 2.7 (95% CI 1.0-7.1)) and alcohol consumption above fourteen units weekly (HR = 3.1 (95% CI 1.1-8.7)). Multivariate analysis, however, found that only low platelet count was independently associated with HCC (HR = 5.5 (95% CI 0.6-5.1)).HCC arises in approximately one fifth of indeterminate liver lesions over 4.6 years and is associated with a low platelet count at the time of first diagnosis of an indeterminate lesion. Incidence of HCC was more common in people with viral hepatitis and in those consuming > 14 units of alcohol per week. Our data may be used to support a strategy of enhanced surveillance in patients with indeterminate lesions.© 2022. The Author(s).
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[2] |
European Association for the Study of the Liver, Clinical Practice Guideline Panel, EASL Governing Board representative, et al. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis-2021 update[J]. J Hepatol, 2021, 75(3): 659-689.
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[3] |
陈曦, 牛佳美, 蒋佩岑, 等. 联合应用两种超声弹性成像技术诊断肝脏局灶性病变良恶性的价值研究[J]. 医学综述, 2021, 27(6): 1227-1234.
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[4] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[5] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[6] |
董丙田, 黄枢. 超声弹性成像在肝脏疾病的临床应用[J]. 医学综述, 2019, 25(5): 1002-1006.
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[7] |
李丹, 王树庚, 赵飞. 晚期肝癌患者化疗栓塞术疗效与血清γ-谷氨酰转肽酶水平相关性分析[J]. 中国医药, 2020, 15(2): 263-266.
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[8] |
刘可, 黄妍卓. 超声弹性成像检测弹性评分及应变率比值在肝结节性质鉴别中的应用[J]. 肝脏, 2020, 25(8): 837-839.
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[9] |
邹雁冰, 袁强. 实时超声弹性成像技术在肝病灶良恶性病变鉴别中的应用价值[J]. 中西医结合肝病杂志, 2021, 31(4): 369-372.
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[10] |
张瑜, 陈琨. 血小板4项参数联合血清AFP水平检测对乙型肝炎肝硬化肝癌的诊断价值研究[J]. 国际检验医学杂志, 2020, 41(23): 2921-2924.
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[11] |
Preoperative serum gamma-glutamyl transferase (γ-GT) levels is significantly related to the prognosis of hepatocellular carcinoma (HCC), but its clinical value in the management of postoperative adjuvant transarterial chemoembolization (PA-TACE) has rarely been explored. This study aimed to investigate whether γ-GT levels could be taken as a biomarker to guide the management of PA-TACE in resectable HCC.HCC patients receiving radical resection were identified through the primary liver cancer big data (PLCBD) from December 2012 to December 2015. Prognostic factors of overall survival (OS) and disease-free survival (DFS) were identified by univariate and multivariate cox analyses, and subgroup analysis was conducted between PA-TACE group and non-TACE stratified by γ-GT levels before and after 1:1 propensity score matching (PSM).γ-GT level was found to be an independent risk factor of OS and DFS in 1847 HCC patients receiving radical resection (both P < 0.05), and patients with elevated γ-GT(> 54.0 U/L) have a shortened median OS and DFS, compared with those with normal γ-GT (both P < 0.001). In the subgroup of patients with normal γ-GT, there were no significant differences between groups of PA-TACE and non-TACE in terms of median OS and DFS before and after PSM (all P > 0.05), and PA-TACE was not a significant prognostic factor of both OS and DFS before and after PSM (all P > 0.05). In the subgroup of patients with elevated γ-GT, significant differences were found between groups of PA-TACE and non-TACE in terms of median OS and DFS before and after PSM (all P < 0.05), and PA-TACE was an independent prognostic factor of both OS and DFS (all P < 0.05).Currently, we concluded that patients with more advanced HCC also have more elevated γ-GT, and these patients with elevated γ-GT would be benefited more from PA-TACE after radical resection.© 2021. The Author(s).
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[12] |
陈惠春, 涂海斌, 林健玲. 超声弹性成像联合血清学检查预测肝细胞癌微血管侵犯研究[J]. 中华肝胆外科杂志, 2021, 27(10): 744-747.
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[13] |
陈君耀, 黎才洋, 官宏勇. 超声弹性成像及彩超血流成像与超声造影在鉴别原发性及转移性肝癌的价值[J]. 中国医学装备, 2022, 19(5): 86-90.
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[14] |
冯硕, 昝立山, 马军, 等. 肝脏MRI联合血清DK K1、GPC3、FOXP3、CXCL13和AFP检测诊断肝细胞癌价值分析[J]. 肝脏, 2020, 25(12): 1282-1285.
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[15] |
Liver biochemical tests are some of the most commonly ordered routine tests in the inpatient and outpatient setting, especially with the automatization of testing in this technological era. These tests include aminotransferases, alkaline phosphatase, gamma-glutamyl transferase, bilirubin, albumin, prothrombin time and international normalized ratio (INR). Abnormal liver biochemical tests can be categorized based on the pattern and the magnitude of aminotransferases elevation. Generally, abnormalities in aminotransferases can be classified into a hepatocellular pattern or cholestatic pattern and can be further sub-classified based on the magnitude of aminotransferase elevation to mild [< 5 × upper limit of normal (ULN)], moderate (> 5-< 15 × ULN) and severe (> 15 × ULN). Hepatocellular pattern causes include but are not limited to; non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, alcohol use, chronic viral hepatitis, liver cirrhosis (variable), autoimmune hepatitis, hemochromatosis, Wilson's disease, alpha-1 antitrypsin deficiency, celiac disease, medication-induced and ischemic hepatitis. Cholestatic pattern causes include but is not limited to; biliary pathology (obstruction, autoimmune), other conditions with hyperbilirubinemia (conjugated and unconjugated). It is crucial to interpret these commonly ordered tests accurately as appropriate further workup, treatment and referral can greatly benefit the patient due to prompt treatment which can improve the natural history of several of the diseases mentioned and possibly reduce the risk of progression to the liver cirrhosis.©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
{{custom_citation.content}}
{{custom_citation.annotation}}
|
{{custom_ref.label}} |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
/
〈 |
|
〉 |